Series A · Raised $74.3M · Oct 2, 2026announcement ↗
Breye Therapeutics
Backed by
BiotechDenmarkbreye.com ↗
🔒 Insider
The founder’s email for Breye Therapeutics, with a short intro note already written for you.
What they do
Breye Therapeutics is a Danish clinical-stage biopharmaceutical company developing oral small-molecule therapies for retinal diseases and patients at risk of vision loss. Its pipeline includes danegaptide and P2X7 receptor antagonists intended to provide anti-inflammatory and neuroprotective effects in ophthalmology.
Hiring outlook
A €67.5 million Series A gives the company scope to advance clinical development, expand translational and regulatory capabilities, and build manufacturing and quality functions. Likely next roles include clinical operations, regulatory affairs, drug development, biostatistics, and research positions, with additional corporate and finance hires as the program advances.
Open roles
Pre-flood window open
Nothing posted yet since the raise, which is exactly when a direct, well-aimed email to a founder beats every job portal. When the postings go up, so does the competition.
Get founders like this to reach you →